Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06810050 · ClinicalTrials.gov registry record · Phase 2

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis (AD), sponsored by CAGE Bio.

Recruiting
Registry status
Phase 2
Development phase
180
Enrollment target
16
Study locations

NCT06810050 is a Phase 2 study of Atopic Dermatitis (AD) that is actively recruiting participants, run by CAGE Bio. The registered enrollment target is 180 participants, above the 85-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (112% higher). The trial reports 16 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06810050, a Phase 2 study of Atopic Dermatitis (AD), is actively recruiting participants, sponsored by CAGE Bio.

RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
16
Study locations

Study Summary

The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis. Participants will: Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks. Keep a diary of when they use the product and complete a form about their symptoms including itching.

Conditions Studied

Atopic Dermatitis (AD)

Interventions

  • DRUG CGB-500 with 0.5% tofacitinib
  • DRUG CGB-500 Ointment with 1% tofacitinib
  • DRUG Vehicle (placebo)

Study Locations (16)

Florida

  • USA and International Research Inc. - Doral
  • FXM Clinical Research - Fort Lauderdale
  • Driven Research - Gables
  • FXM Clinical Research Miami, LLC - Miami
  • FXM Clinical Research Miramar, LLC - Miramar
  • Cordova Research Institute - Sweetwater

California

  • Center for Dermatology Clinical Research Inc. - Fremont
  • Ablon Skin Institute and Research Center - Manhattan Beach
  • TCR Medical Corporation - San Diego
  • Syrentis Clinical Research - Santa Ana

Indiana

  • The Indiana Clinical Trials Center, PC - Plainfield

Massachusetts

  • Metro Boston Clinical Partners - Brighton

Minnesota

  • J&S Studies, Inc. - New Brighton

Nevada

  • JDR Dermatology Research - Las Vegas

Tennessee

  • Tennessee Clinical Research Center - Nashville

Texas

  • DermResearch - Austin

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2024-12-18
Est. Completion 2025-10-30
Phase Phase 2

Sponsor

CAGE Bio

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06810050

The ClinicalTrials.gov registry entry for NCT06810050 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (112% higher). The listed sponsor is CAGE Bio, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 3 interventions - of which CGB-500 with 0.5% tofacitinib is the first listed.

NCT06810050 reports 16 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT06810050 about?

NCT06810050 is a clinical study titled "Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis". The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the ...

What is the current status of trial NCT06810050?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-12-18. Estimated completion is 2025-10-30.

What conditions does trial NCT06810050 study?

This clinical trial studies the following conditions: Atopic Dermatitis (AD).

What interventions are being tested in trial NCT06810050?

The interventions under investigation include: CGB-500 with 0.5% tofacitinib (DRUG), CGB-500 Ointment with 1% tofacitinib (DRUG), Vehicle (placebo) (DRUG).

Who is sponsoring clinical trial NCT06810050?

This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06810050 being conducted?

This trial has 16 study locations across California, Florida, Indiana, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis (AD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis (AD)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.